Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 1
2015 1
2016 2
2017 2
2019 3
2020 2
2021 2
2022 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

13 results

Results by year

Filters applied: . Clear all
Page 1
Intravitreal Ranibizumab Injection for the Treatment of Retinopathy of Prematurity.
Aldebasi T, Guma MA, Bashir R, Al Saif S, Altwaijri WA, Al Bekairy AM. Aldebasi T, et al. Med Princ Pract. 2019;28(6):526-532. doi: 10.1159/000500310. Epub 2019 Apr 16. Med Princ Pract. 2019. PMID: 30995663 Free PMC article.
OBJECTIVES: To evaluate the efficacy of a single injection of 0.3 mg intravitreal ranibizumab for the treatment of retinopathy of prematurity (ROP). METHODS: We conducted this retrospective case series study at King Abdul Aziz Medical City, Riyadh, Saudi Arab …
OBJECTIVES: To evaluate the efficacy of a single injection of 0.3 mg intravitreal ranibizumab for the treatment of retinopathy of …
Involution of retinopathy of prematurity and neurodevelopmental outcomes after intravitreal bevacizumab treatment.
Chang YS, Chen YT, Lai TT, Chou HC, Chen CY, Hsieh WS, Yang CM, Yeh PT, Tsao PN. Chang YS, et al. PLoS One. 2019 Oct 16;14(10):e0223972. doi: 10.1371/journal.pone.0223972. eCollection 2019. PLoS One. 2019. PMID: 31618256 Free PMC article.
This single-centered, retrospective cohort study investigated the timing of involution of retinopathy of prematurity (ROP) and retinal vascularization to zone III after intravitreal bevacizumab (IVB) treatment and its possible impacts on postnat …
This single-centered, retrospective cohort study investigated the timing of involution of retinopathy of prematurity (R …
Treatment of retinopathy of prematurity (ROP) outside International Classification of ROP (ICROP) guidelines.
Rajan RP, Kohli P, Babu N, Dakshayini C, Tandon M, Ramasamy K. Rajan RP, et al. Graefes Arch Clin Exp Ophthalmol. 2020 Jun;258(6):1205-1210. doi: 10.1007/s00417-020-04706-8. Epub 2020 Apr 22. Graefes Arch Clin Exp Ophthalmol. 2020. PMID: 32322963
AIM: To evaluate the incidence and clinical indications for which eyes were treated for retinopathy of prematurity (ROP) outside the guidelines set by International Classification of ROP (ICROP). ...Pre-plus disease was present in 11 eyes (33.3%).After the tr …
AIM: To evaluate the incidence and clinical indications for which eyes were treated for retinopathy of prematurity (ROP …
Effects of Intravitreal Ranibizumab in the Treatment of Retinopathy of Prematurity in Chinese Infants.
Yi Z, Su Y, Zhou Y, Zheng H, Ye M, Xu Y, Chen C. Yi Z, et al. Curr Eye Res. 2016 Aug;41(8):1092-1097. doi: 10.3109/02713683.2015.1084643. Epub 2015 Nov 18. Curr Eye Res. 2016. PMID: 26580816
PURPOSE: To evaluate the efficacy associated with intravitreal ranibizumab in the treatment of retinopathy of prematurity (ROP). METHODS: A retrospective case series study. ...CONCLUSION: Intravitreal ranibizumab is effective for the treatment of retinopat …
PURPOSE: To evaluate the efficacy associated with intravitreal ranibizumab in the treatment of retinopathy of prematurity …
Comparison of two different doses of intravitreal aflibercept in the treatment of retinopathy of prematurity.
Ekinci DY, Vural AD. Ekinci DY, et al. J AAPOS. 2021 Apr;25(2):93.e1-93.e5. doi: 10.1016/j.jaapos.2020.11.020. Epub 2021 Apr 24. J AAPOS. 2021. PMID: 33905838
PURPOSE: To compare the effectiveness of 0.4 mg/0.01 ml ("low dose") and 1 mg/0.025 ml ("standard dose") intravitreal aflibercept (IVA) in the treatment of retinopathy of prematurity (ROP). METHODS: The medical records of patients treated with the lower dose …
PURPOSE: To compare the effectiveness of 0.4 mg/0.01 ml ("low dose") and 1 mg/0.025 ml ("standard dose") intravitreal aflibercept (IVA) in t …
Anti-Vascular Endothelial Growth Factor Therapy for Primary Treatment of Type 1 Retinopathy of Prematurity: A Report by the American Academy of Ophthalmology.
VanderVeen DK, Melia M, Yang MB, Hutchinson AK, Wilson LB, Lambert SR. VanderVeen DK, et al. Ophthalmology. 2017 May;124(5):619-633. doi: 10.1016/j.ophtha.2016.12.025. Epub 2017 Mar 22. Ophthalmology. 2017. PMID: 28341474 Review.
PURPOSE: To review the available evidence on the ocular safety and efficacy of anti-vascular endothelial growth factor (VEGF) agents for the treatment of retinopathy of prematurity (ROP) compared with laser photocoagulation therapy. ...CONCLUSIONS: Cur …
PURPOSE: To review the available evidence on the ocular safety and efficacy of anti-vascular endothelial growth factor (VEGF) agents for the …
Effects of Early Treatment of Retinopathy of Prematurity at a Tertiary Care Hospital in Saudi Arabia: A Retrospective Study.
Danish E, Hadrawi M, Tayyib A, Babgi R. Danish E, et al. J Pediatr Ophthalmol Strabismus. 2021 Jul-Aug;58(4):240-245. doi: 10.3928/01913913-20210122-02. Epub 2021 Jul 1. J Pediatr Ophthalmol Strabismus. 2021. PMID: 34288772
PURPOSE: To estimate the prevalence of retinopathy of prematurity (ROP) among high-risk neonates and to illuminate the benefits of early treatment in type 2 ROP (zone II, stage 3 without plus) and ROP milder than type 1 with pre-plus disease (zone …
PURPOSE: To estimate the prevalence of retinopathy of prematurity (ROP) among high-risk neonates and to illuminate the …
Evaluation of clinical profile and screening guidelines of retinopathy of prematurity in an urban level III neonatal intensive care unit.
Sanghi G, Sawhney JS, Kaur S, Kumar N. Sanghi G, et al. Indian J Ophthalmol. 2022 Jul;70(7):2476-2479. doi: 10.4103/ijo.IJO_1925_21. Indian J Ophthalmol. 2022. PMID: 35791138 Free PMC article.
PURPOSE: To evaluate the clinical profile and screening guidelines of retinopathy of prematurity (ROP) in an urban level III neonatal intensive care unit (NICU). ...CONCLUSION: The majority of infants developing ROP in a level III urban N …
PURPOSE: To evaluate the clinical profile and screening guidelines of retinopathy of prematurity (ROP) in an urban leve …
FLUORESCEIN ANGIOGRAPHIC EVALUATION OF PERIPHERAL RETINAL VASCULATURE AFTER PRIMARY INTRAVITREAL RANIBIZUMAB FOR RETINOPATHY OF PREMATURITY.
Harper CA 3rd, Wright LM, Young RC, Read SP, Chang EY. Harper CA 3rd, et al. Retina. 2019 Apr;39(4):700-705. doi: 10.1097/IAE.0000000000001996. Retina. 2019. PMID: 29300248
PURPOSE: To evaluate angiographic findings in neonates up to 150 weeks postmenstrual age who received intravitreal ranibizumab for primary treatment of Type 1 retinopathy of prematurity. METHODS: Retrospective evaluation of fluorescein angiogram findings was …
PURPOSE: To evaluate angiographic findings in neonates up to 150 weeks postmenstrual age who received intravitreal ranibizumab for primary t …
Involution patterns of retinopathy of prematurity after treatment with intravitreal bevacizumab: implications for follow-up.
Isaac M, Tehrani N, Mireskandari K; Medscape. Isaac M, et al. Eye (Lond). 2016 Mar;30(3):333-41. doi: 10.1038/eye.2015.289. Epub 2016 Feb 12. Eye (Lond). 2016. PMID: 26869159 Free PMC article.
PURPOSE: To describe involution patterns following monotherapy with intravitreal bevacizumab injection (IVB) for type 1 retinopathy of prematurity (ROP) in zone I or zone II posterior. METHODS: A retrospective chart review of infants treated wit …
PURPOSE: To describe involution patterns following monotherapy with intravitreal bevacizumab injection (IVB) for type 1 retinopathy …
13 results